[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100528747":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":66,"centralContacts":71,"locations":81,"responsibleParty":202,"collaborators":10,"id":206,"slug":207,"hasResults":208,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":208,"sex":214,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":10,"studyType":220,"phases":10,"briefSummary":221,"conditions":222,"keywords":10,"overallStatus":84,"whyStopped":10,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":233},{"fullName":5,"class":6},"424 General Military Hospital","OTHER",[8,14,19,25,29,33],{"label":9,"type":10,"description":11,"interventionNames":12},"Romo-Zol group",null,"Postmenopausal women treated with romosozumab for 12 months will receive a single zoledronate infusion (5mg) at 1 month after the last romosozumab dose",[13],"Drug: Zoledronate",{"label":15,"type":10,"description":16,"interventionNames":17},"Romo-Dmab group","Postmenopausal women treated with romosozumab for 12 months will receive subcutaneous denosumab injections (60mg) bi-annually for 12 months starting at 1 month after the last romosozumab dose",[18],"Drug: Denosumab",{"label":20,"type":10,"description":21,"interventionNames":22},"Romo-PTH group","Postmenopausal women treated with romosozumab for 12 months will receive daily injections of teriparatide 20μg or abaloparatide 80μg for 12 months starting at 1 month after the last romosozumab dose",[23,24],"Drug: Teriparatide","Drug: Abaloparatide Injection (80 mcg)",{"label":26,"type":10,"description":27,"interventionNames":28},"PTH-Zol group","Postmenopausal women treated with teriparatide for 24 months or abaloparatide for 18 monthswill receive a single zoledronate infusion (5mg) at 1 month after the last romosozumab dose",[13],{"label":30,"type":10,"description":31,"interventionNames":32},"PTH-Dmab group","Postmenopausal women treated with teriparatide for 24 months or abaloparatide for 18 months will receive subcutaneous denosumab injections (60mg) bi-annually for 12 months",[18],{"label":34,"type":10,"description":35,"interventionNames":36},"TPTD-Romo group","Postmenopausal women treated with teriparatide for 24 months or abaloparatide for 18 months will receive month injections of romosozumab for 12 months",[37],"Drug: Romosozumab",[39,46,52,57,62],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","Zoledronate","intravenous infusion",[26,9],[45],"zoledronic acid; zolendronate",{"type":40,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"Denosumab","subcutaneous injection",[30,15],[51],"Dmab",{"type":40,"name":53,"description":48,"armGroupLabels":54,"otherNames":55},"Teriparatide",[20],[56],"TPTD",{"type":40,"name":58,"description":48,"armGroupLabels":59,"otherNames":60},"Romosozumab",[34],[61],"Romo",{"type":40,"name":63,"description":64,"armGroupLabels":65,"otherNames":10},"Abaloparatide Injection (80 mcg)","daily subcutaneous injection",[20],[67],{"name":68,"affiliation":69,"role":70},"Willem Lems, Prof","ECTS Clinical Action Group","STUDY_CHAIR",[72,78],{"name":73,"role":74,"phone":75,"phoneExt":76,"email":77},"Athanasios D Anastasilakis, PhD","CONTACT","2310381431","+30","a.anastasilakis@gmail.com",{"name":79,"role":74,"phone":10,"phoneExt":10,"email":80},"John Carey, Prof","john.j.carey@universityofgalway.ie",[82,100,111,122,137,154,172,188],{"facility":83,"status":84,"city":85,"state":10,"zip":86,"country":87,"countryCode":88,"cosmosGeoPoint":89,"geoPoint":94,"contacts":95},"251 Airforce & VA General Hospital","RECRUITING","Athens","11525","Greece","GR",{"type":90,"coordinates":91},"Point",[92,93],23.72784,37.98376,{"lat":93,"lon":92},[96],{"name":97,"role":74,"phone":98,"phoneExt":10,"email":99},"Polyzois Makras, PhD","+302107463606","pmakras@gmail.com",{"facility":101,"status":84,"city":85,"state":10,"zip":102,"country":87,"countryCode":88,"cosmosGeoPoint":103,"geoPoint":105,"contacts":106},"First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens","11527",{"type":90,"coordinates":104},[92,93],{"lat":93,"lon":92},[107],{"name":108,"role":74,"phone":109,"phoneExt":10,"email":110},"Maria P Yavropoulou, Consultant","+30 2132060800","myavropoulou@med.uoa.gr",{"facility":112,"status":84,"city":85,"state":10,"zip":113,"country":87,"countryCode":88,"cosmosGeoPoint":114,"geoPoint":116,"contacts":117},", KAT General Hospital","14561",{"type":90,"coordinates":115},[92,93],{"lat":93,"lon":92},[118],{"name":119,"role":74,"phone":120,"phoneExt":10,"email":121},"Symeon Tournis, PhD","+30 2132086000","stournis@med.uoa.gr",{"facility":5,"status":84,"city":123,"state":10,"zip":124,"country":87,"countryCode":88,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Thessaloniki","56429",{"type":90,"coordinates":126},[127,128],22.93493,40.64072,{"lat":128,"lon":127},[131,133],{"name":73,"role":74,"phone":132,"phoneExt":10,"email":77},"+302310381697",{"name":134,"role":74,"phone":135,"phoneExt":10,"email":136},"Stergios A Polyzos, PhD","+302310455780","stergios@endo.gr",{"facility":138,"status":84,"city":139,"state":10,"zip":10,"country":140,"countryCode":141,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico","Milan","Italy","IT",{"type":90,"coordinates":143},[144,145],9.18951,45.46427,{"lat":145,"lon":144},[148,151],{"name":149,"role":74,"phone":10,"phoneExt":10,"email":150},"Cristina Eller-Vainicher","eller.vainicher@gmail.com",{"name":152,"role":153,"phone":10,"phoneExt":10,"email":10},"Giorgia Grassi, MD","SUB_INVESTIGATOR",{"facility":155,"status":84,"city":156,"state":10,"zip":157,"country":140,"countryCode":141,"cosmosGeoPoint":158,"geoPoint":162,"contacts":163},"Campus Bio-Medico University","Roma","00128",{"type":90,"coordinates":159},[160,161],11.10642,44.99364,{"lat":161,"lon":160},[164,167,169,171],{"name":165,"role":74,"phone":10,"phoneExt":10,"email":166},"Andrea Palermo, Ass Prof","A.Palermo@unicampus.it",{"name":168,"role":74,"phone":10,"phoneExt":10,"email":10},"Gaia Tabacco, PhD",{"name":170,"role":153,"phone":10,"phoneExt":10,"email":10},"Anda Naciu, PhD",{"name":168,"role":153,"phone":10,"phoneExt":10,"email":10},{"facility":173,"status":84,"city":174,"state":10,"zip":175,"country":140,"countryCode":141,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"Department of Medicine, Surgery and Neurosciences, University of Siena","Siena","53100",{"type":90,"coordinates":177},[178,179],11.33064,43.31822,{"lat":179,"lon":178},[182,185,187],{"name":183,"role":74,"phone":10,"phoneExt":10,"email":184},"Luigi Gennari, prof","gennari@unisi.it",{"name":186,"role":74,"phone":10,"phoneExt":10,"email":10},"Daniela Merlotti",{"name":186,"role":153,"phone":10,"phoneExt":10,"email":10},{"facility":189,"status":84,"city":190,"state":10,"zip":10,"country":140,"countryCode":141,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"University-Hospital S. Maria della Misericordia","Udine",{"type":90,"coordinates":192},[193,194],13.23715,46.0693,{"lat":194,"lon":193},[197,200],{"name":198,"role":74,"phone":10,"phoneExt":10,"email":199},"Fabio Vescini","fabio.vescini@asufc.sanita.fvg.it",{"name":201,"role":153,"phone":10,"phoneExt":10,"email":10},"Antonio Salcuni",{"type":203,"investigatorFullName":204,"investigatorTitle":205,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Athanasios D. Anastasilakis","Head of the Department of Endocrinology","100528747","sequential-therapies-after-osteoanabolic-treatment-100528747",false,"NCT06164795","Sequential Therapies After Osteoanabolic Treatment","Efficacy of Sequential Therapies After Osteoanabolic Treatment in Postmenopausal Women With Severe Osteoporosis: the Sequential Treatment After Romosozumab and Teriparatide\u002FAbaloparatide (START) Study","START","Inclusion Criteria:\n\n• Postmenopausal women treated with severe osteoporosis completing their course with romosozumab or teriparatide\n\nExclusion Criteria:\n\n* a bone disease other than postmenopausal osteoporosis\n* use of medications other than romosozumab or teriparatide affecting bone metabolism during the last 12 months before entering the study\n* creatinine clearance \\\u003C60 mL\u002Fmin\u002F1.73 m2\n* liver failure\n* any type of cancer\n* uncontrolled endocrine diseases\n* serum 25-hydroxy vitamin D (25-OHD) concentrations lower than 20 ng\u002FmL (50 nmol\u002FL)\n* hypersensitivity to denosumab or zoledronate or teriparatide or romosozumab or any of the excipients","FEMALE","50 Years","85 Years",{"count":218,"type":219},150,"ESTIMATED","OBSERVATIONAL","12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolics",[223],"Osteoporosis, Postmenopausal","2025-04-24",{"date":226,"type":227},"2025-04-27","ACTUAL",{"date":229,"type":227},"2023-11-25",{"date":231,"type":219},"2027-05",{"name":5,"class":6},8]